Terapie combinate e medicina personalizzata

Combination therapy targets multiple cancer-related pathways simultaneously, reducing drug resistance emergence. A single drug targets only one pathway, allowing resistant cells to develop. Combined drugs also produce synergistic effects, lowering therapeutic dosages while increasing treatment efficiency and cytotoxicity in cancer cells specifically, while reducing side effects on normal cells.

Both drugs enter normal and cancer cells, but their effects differ by cell type. In normal cells, they cancel each other's effects and the cell survives. In cancer cells, ABC transporters selectively pump out caspase inhibitors while retaining flavopiridol, which induces apoptosis. This selective mechanism demonstrates how combination therapy achieves cancer-specific killing.

Personalized medicine tailors treatment based on individual genetic profiles obtained through tumor biopsy and genome sequencing. This approach identifies specific mutations and biochemical pathway changes in each patient's tumor. By targeting these unique genetic characteristics, personalized medicine increases treatment effectiveness, reduces drug toxicity, and improves patient compliance compared to one-size-fits-all approaches.

Imatinib is a specific kinase inhibitor that targets the BCR-ABL1 fusion protein, which results from chromosomal translocation in 15-20 percent of leukemia cases. By inhibiting BCR-ABL1 activity, imatinib slows mutant cell growth. Genetic screening identifies patients with this mutation, allowing targeted imatinib therapy that significantly increases survival rates.

Cancer cells overexpress carbonic anhydrase to neutralize the acidic, hypoxic tumor microenvironment where interior cells would otherwise die. This enzyme catalyzes carbon dioxide conversion to bicarbonate, creating favorable survival conditions. Acetazolamide inhibits carbonic anhydrase, accelerating cancer cell death when combined with sulforaphane for enhanced therapeutic effect.

Personalized medicine is personalized, integrating genetic profiles to target therapy and reduce toxicity. It is preventive, allowing early intervention in high-risk patients like those with BRCA1 or BRCA2 mutations. It is predictive, using gene expression profiles to assess metastasis risk and guide treatment intensity. Finally, it is participatory, as less toxic, more effective treatments improve patient compliance.

Cancer involves multiple genetic mutations and phenotypes that vary among patients and disease stages. This heterogeneity means a single treatment cannot address all cases equally. Patient-specific approaches based on individual genetic profiles enable precise targeting of the unique mutations driving each patient's cancer, improving prevention and treatment efficiency compared to standardized protocols.